Fresenius SE & Co KGaA (FRE.HA)
| Previous Close | 29.88 |
| Open | 29.83 |
| Bid | 29.42 x N/A |
| Ask | 29.56 x N/A |
| Day's Range | 29.83 - 29.83 |
| 52 Week Range | 24.30 - 31.08 |
| Volume | |
| Avg. Volume | 73 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Fresenius SE & Co. KGaA (ETR:FRE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Fresenius SE KGaA's (ETR:FRE) stock is up by a considerable 19% over the past three months. But the company's key...
- Simply Wall St.
Investors five-year losses continue as Fresenius SE KGaA (ETR:FRE) dips a further 3.8% this week, earnings continue to decline
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
- Reuters
UPDATE 2-Fresenius raises outlook on strong quarterly results, exits Vamed
German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its full-year outlook. First-quarter earnings before interest and tax (EBIT) were 633 million euros ($680 million), above analysts' expectations of 606 million euros, according to a consensus of forecasts from Vara Research. In a bid to get leaner, Fresenius also said that it would sell its investment unit, Fresenius Vamed, completing its portfolio restructuring.
